287 related articles for article (PubMed ID: 7710667)
1. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
[TBL] [Abstract][Full Text] [Related]
2. Total and paramagnetic metals in human substantia nigra and its neuromelanin.
Zecca L; Swartz HM
J Neural Transm Park Dis Dement Sect; 1993; 5(3):203-13. PubMed ID: 8396395
[TBL] [Abstract][Full Text] [Related]
3. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
[TBL] [Abstract][Full Text] [Related]
4. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy.
Enochs WS; Nilges MJ; Swartz HM
J Neurochem; 1993 Jul; 61(1):68-79. PubMed ID: 8390568
[TBL] [Abstract][Full Text] [Related]
5. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
[TBL] [Abstract][Full Text] [Related]
6. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
8. Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target.
Mitra R; Premraj L; Khoo TK
Parkinsonism Relat Disord; 2023 Jul; 112():105448. PubMed ID: 37236833
[TBL] [Abstract][Full Text] [Related]
9. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems.
Zareba M; Bober A; Korytowski W; Zecca L; Sarna T
Biochim Biophys Acta; 1995 Jun; 1271(2-3):343-8. PubMed ID: 7605801
[TBL] [Abstract][Full Text] [Related]
10. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C
Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907
[TBL] [Abstract][Full Text] [Related]
11. Modifications of the iron-neuromelanin system in Parkinson's disease.
Fasano M; Bergamasco B; Lopiano L
J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
[TBL] [Abstract][Full Text] [Related]
12. New face of neuromelanin.
Double KL; Halliday GM
J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation.
Korytowski W; Sarna T; Zar ba M
Arch Biochem Biophys; 1995 May; 319(1):142-8. PubMed ID: 7771778
[TBL] [Abstract][Full Text] [Related]
15. Neuromelanin and Parkinson's disease.
Marsden CD
J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
[TBL] [Abstract][Full Text] [Related]
16. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
[TBL] [Abstract][Full Text] [Related]
17. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
[TBL] [Abstract][Full Text] [Related]
18. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
Knörle R
Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
[TBL] [Abstract][Full Text] [Related]
19. [The role of neuromelanin in Parkinson's disease--new concepts].
Stepień K; Dzierzega-Lecznar A; Tam I
Wiad Lek; 2007; 60(11-12):563-9. PubMed ID: 18540183
[TBL] [Abstract][Full Text] [Related]
20. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.
Zecca L; Shima T; Stroppolo A; Goj C; Battiston GA; Gerbasi R; Sarna T; Swartz HM
Neuroscience; 1996 Jul; 73(2):407-15. PubMed ID: 8783258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
